New Insights into the Management of Hypertension and Cardiovascular Risk with Angiotensin Receptor Blockers: Observational Studies Help Us?

Assen Goudev*
Department of Cardiology, Queen Giovanna University Hospital, 8 Bialo More St, Sofia 1527, Bulgaria

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 1598
Abstract HTML Views: 673
PDF Downloads: 351
Total Views/Downloads: 2622
Unique Statistics:

Full-Text HTML Views: 673
Abstract HTML Views: 386
PDF Downloads: 261
Total Views/Downloads: 1320

Creative Commons License
© Assen Goudev; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Cardiology, Queen Giovanna University Hospital, 8 Bialo More St, Sofia 1527, Bulgaria; Tel: +35929432584; Fax: +35929432126; E-mail:


Post-marketing observational studies are valuable for establishing the real-world effectiveness of treatment regimens in routine clinical practice as they typically monitor a diverse population of patients over many months. This article reviews recent observational studies of angiotensin receptor blockers (ARBs) for the management of hypertension: the 6-month eprosartan POWER study (n~29,400), the 3-month valsartan translational research programme (n~19,500), the 9-month irbesartan Treat to Target study (n=14,200), the 6-month irbesartan DO-IT survey (n~3300) and the 12-week candesartan CHILI survey programme (n=4600). Reduction in blood pressure with ARBs reported across these studies appears to be comparable for the different agents, although direct comparisons between studies cannot be made owing to different treatment durations and baseline patient demographics. Of these studies, the eprosartan POWER study, 2 of the 7 studies in the valsartan translational research programme, and the candesartan CHILI Triple T study measured total cardiovascular risk, as recommended in the 2013 European Society of Cardiology-European Society of Hypertension guidelines. The POWER study confirmed the value of the Systemic Coronary Risk Evaluation (SCORE) to accurately assess total cardiovascular risk.

With the advent of new healthcare practices, such as the use of electronic health records (EHRs), observational studies in larger patient populations will become possible. In the future, algorithms embedded in EHR systems could evolve as decision support tools to inform on patient care.

Keywords: : Angiotensin receptor blockers, blood pressure, candesartan, eprosartan, irbesartan, observational studies, Systemic Coronary Risk Evaluation, valsartan..